Novocure tanks after cancer treatment fails to meet late-stage trial goal

NovoCure

18/06/2026 12:32

** Shares of cancer therapy maker Novocure NVCR.O down 21.6% at $14 in the pre-market trading
** Co's treatment for newly diagnosed brain tumors did not meet the main goal of a late-stage study
** Says the trial did not show an improvement in overall survival for patients whose treatment started early compared to those starting at the maintenance stage.
** Trial demonstrates durable survival benefit for patients in both arms of the trial with no new safety signals observed, co says
** As of last close, stock was up 38% YTD
     

 (Reporting by Zakia Mariyam in Bengaluru)
 ((zakia.mariyam@thomsonreuters.com))